Helping You Build Wealth With Honest Research
Since 1996. Read On...

The Best Asset Allocation for Your Equity Portfolio

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

Trusted by a Strong Community of Investors Since 2002
Access Our Premium Blue-Chip Recommendations


Get Instant Access

**Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.

AD

5 Midcap Stocks with Blockbuster Q4 Results

May 25, 2026

5 Midcap Stocks with Blockbuster Q4 ResultsImage source: DEVASHISH_RAWAT/www.istockphoto.com

The financial results season is here again, and India Inc's Q4 FY26 results reflect mixed earnings for the quarter.

Due to geopolitical tensions, high fuel prices, weak global demand, and other factors, businesses are suffering across the globe, and India is not an exception.

Having said that, the Q4 FY26 results have been relatively better than the previous few quarters. Interestingly, there are a handful of midcap companies that have delivered strong Q4 earnings that are worth investors' attention.

In this editorial, we will be exploring five such midcap stocks that have delivered blockbuster Q4 results, and we will also look at the bigger picture that is the entire FY26 performance.

#1 Neuland Laboratories

Neuland Laboratories is a manufacturer and supplier of bulk drugs catering to domestic as well as international markets.

This pharma company specialises in prime Active Pharmaceutical Ingredients (APIs), specialty APIs, or niche APIs, and also offers customer manufacturing solutions (CMS).

Q4FY26 Performance

Basis Q4FY25 Q4FY26 % Change YoY
Total Income (Rs m) 3358.0 7887.0 134.9
PAT (Rs m) 277.0 2125.0 666.3

During Q4FY26, the total income of the company went up to Rs 7,887 million (m), from Rs 3,358 m in the corresponding quarter last fiscal, a 134.9% YoY growth.

During the quarter, this company delivered a whopping 666.3% YoY profit growth. The profit after tax (PAT) went up from Rs 277 m to Rs 2,125 m during the period.

The PAT margin grew from a mere 8.3% in Q4FY25 to 26.9% in Q4FY26.

This significant rise in the profit of the company also made earnings per share (EPS) increase from Rs 21.6 per share to Rs 165.6 per share during the period.

However, what's more interesting is that the company achieved this exponential Q4 result while reducing its debt. Neuland reduced its net debt from Rs 2,287 m in Q4FY25 to Rs 1,568 m during Q4FY25.

Another interesting fact is that the company has been increasing its CMS segment, and that is evident from the revenue share of the CMS business segment, which has surged from 34% during Q4FY25 to 68% in Q4FY26.

This has made the share of prime and specialty APIs in the revenue come down to 18% and 8%, respectively, from the 40% and 19% in Q4FY25.

Coming to the overall performance during FY26, the total income surged from Rs 14,973 m in FY25 to Rs 20,531 m. PAT increased from Rs 2,594 m to Rs 3,631 m during the fiscal year.

The company has a return on capital employed (ROCE) of 26.1% as of FY26.

Looking ahead, the company has 204 patent filings awaiting approval. Then there are more than a thousand Drug Master Files (DMFs), along with three USDMFs that the company filed during FY26.

Neuland is building a big research and development (R&D) center, which will span 1.4 lakh sq. ft. of area in Genome Valley, Hyderabad.

Want To Read The Full Article?

Enter your email to continue reading on Equitymaster.

Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster covering exciting investing ideas and opportunities in India.

Equitymaster requests your view! Post a comment on "5 Midcap Stocks with Blockbuster Q4 Results". Click here!